ScholarIQanswers from OpenAlex & ORCID
David Lebwohl
ResearcherPublications, citations & collaboration network
David Lebwohl is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does David Lebwohl have?
ScholarIQindexed works
David Lebwohl has 90 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does David Lebwohl have?
ScholarIQcitation count
David Lebwohl has 27,486 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of David Lebwohl?
ScholarIQh-index
David Lebwohl has an h-index of 44 in OpenAlex.
What is the i10-index of David Lebwohl?
ScholarIQi10-index
David Lebwohl has an i10-index of 71 in OpenAlex.
What is the ORCID of David Lebwohl?
ScholarIQorcid
The ORCID for David Lebwohl is on the source record.
What is the OpenAlex record for David Lebwohl?
ScholarIQopenalex
The OpenAlex for David Lebwohl is on the source record.
What are the most-cited papers on David Lebwohl?
ScholarIQmost cited works
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
Shannon L. Maude, Theodore W. Laetsch, Jochen Buechner, Susana Rives, Michael Boyer, Henrique Bittencourt, Peter Bader, Michael R. Verneris, Heather E. Stefanski, Gary D. Myers, Muna Qayed, Barbara De Moerloose, Hidefumi Hiramatsu, Krysta Schlis, Kara L. Davis, Paul L. Martin, Eneida R. Nemecek, Gregory A. Yanik, Christina Peters, André Baruchel, Nicolas Boissel, Françoise Méchinaud, Adriana Balduzzi, Joerg Krueger, Carl H. June, Bruce L. Levine, Patricia A. Wood, Tetiana Taran, Mimi Leung, Karen T. Mueller, Yiyun Zhang, Kapildeb Sen, David Lebwohl, Michael A. Pulsipher, Stephan A. Grupp
Everolimus for Advanced Pancreatic Neuroendocrine Tumors
James C. Yao, Manisha H. Shah, Tetsuhide Ito, C. Lombard Bohas, Edward M. Wolin, Eric Van Cutsem, Timothy J. Hobday, Takuji Okusaka, Jaume Capdevila, Elisabeth G.E. de Vries, Paola Tomassetti, Marianne Pavel, Sakina Hoosen, T Haas, Jeremie Lincy, David Lebwohl, Kjell Öberg
Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study
Marianne Pavel, John D. Hainsworth, Éric Baudin, Marc Peeters, Dieter Hörsch, Robert Winkler, Judith Klimovsky, David Lebwohl, Valentine Jehl, Edward M. Wolin, Kjell Öberg, Eric Van Cutsem, James C. Yao
Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial
John J. Bissler, J.C. Kingswood, Elżbieta Radzikowska, Bernard A. Zonnenberg, Michael Frost, Е. Д. Белоусова, Matthias Sauter, Norio Nonomura, Susanne Brakemeier, Petrus J. de Vries, Vicky Whittemore, David Chen, Tarek Sahmoud, Gaurav Shah, Jeremie Lincy, David Lebwohl, Klemens Budde
Daily Oral Everolimus Activity in Patients With Metastatic Pancreatic Neuroendocrine Tumors After Failure of Cytotoxic Chemotherapy: A Phase II Trial
James C. Yao, Catherine Lombard‐Bohas, Éric Baudin, Larry K. Kvols, Philippe Rougier, Philippe Ruszniewski, Sakina Hoosen, J. Peter, T Haas, David Lebwohl, Eric Van Cutsem, Matthew H. Kulke, Timothy J. Hobday, Thomas M. O’Dorisio, Manisha H. Shah, Guillaume Cadiot, Gabriele Luppi, James Posey, Bertram Wiedenmann